短链脂肪酸对肥胖相关喘的多目标作用:干预潜力和挑战
Mingxin Liang1,2, Lan Li2, Juan Fan3
1School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, China.
Clinical reviews in allergy & immunology
|October 28, 2025
概括
与肥胖相关的喘包括炎症和代谢问题,症状恶化. 来自肠道微生物的短链脂肪酸 (SCFA) 是破坏这种循环的有希望的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
- 肺部病理学 肺部病理学
背景情况:
- 肥胖和喘的患病率不断上升,给公共卫生带来了重大挑战.
- 与肥胖相关的喘是一种独特的表型,其特点是慢性炎症和代谢失调.
- 脂肪组织,肠道微生物群和肺炎之间的复杂相互作用推动了疾病的进展.
研究的目的:
- 为了阐明与肥胖相关的喘的发病原因.
- 确定关键的分子机制和涉及的病理成分.
- 探索这种情况的潜在治疗点.
主要方法:
- 关于与肥胖相关的喘当前文献的综述.
- 分析代谢失调,肠道微生物群失调和炎症之间的相互作用.
- 研究短链脂肪酸 (SCFA) 作为治疗剂的作用.
主要成果:
- 与肥胖相关的喘表现出一种自我强化的病理循环,涉及脂肪功能障碍,肠道失调,全身和肺炎.
- 与经典喘相比,这种表型呈现出临床严重性增加,恶化和治疗反应减少.
- 短链脂肪酸 (SCFA) 显示出减轻炎症,调节免疫反应和保护上皮屏障的潜力.
结论:
- 短链脂肪酸 (SCFA) 是肥胖相关喘的有前途的治疗策略.
- 通过饮食,微生物补充剂或便微生物群移植调节SCFA水平可能会破坏疾病周期.
- 针对SCFA提供了一种新的方法来管理这种复杂的并发症.
相关概念视频
Asthma-I: Introduction
3.4K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.4K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K


